The novel boron-based carbonic anhydrase IX and XII inhibitor AM_DB induces cytotoxic effects and enhances the response of ovarian cancer cells to carboplatin
Year: 2026
Type: article
Abstract: Carbonic anhydrases IX and XII have become promising therapeutic targets in ovarian cancer, the deadliest gynecological malignancy. In this study, the boron-containing compound AM_DB was synthesized and tested for its ability to inhibit carbonic anhydrases. Structural analysis allowed us to understand its binding interactions within the enzyme active site. The in vitro anti-tumor potential of AM_DB, both alone and in combination with carboplatin, was evaluated in the SKOV-3, Caov-3, and OVCAR-3 cell lines. AM_DB decreased cell viability in a dose-dependent manner, especially in SKOV-3 cells, caused G2/M arrest, and elevated ROS production without inducing apoptosis. Notably, AM_DB increased carboplatin’s cytotoxic effects under hypoxia, linked to cytoskeletal disruption and reduced colony formation. Importantly, AM_DB showed no hemolytic activity. Although a comparable reduction in viability was observed in CCD-18Co and ovarian cancer cell lines, overall viability remained around 80%, indicating that AM_DB does not induce pronounced cytotoxic effects in non-tumor cells under the tested conditions. Overall, these results support the importance of targeting hCA IX and hCA XII and highlight AM_DB as a promising adjunct to standard chemotherapy for ovarian cancer.
Source: Journal of Ovarian Research
Institutions: Lebanese University, Centre National de la Recherche Scientifique, Institut Charles Gerhardt Montpellier, Institute of Biostructure and Bioimaging, University of Florence, Autonomous University of Chihuahua, École Nationale Supérieure de Chimie de Montpellier, Université de Montpellier, Institut des Biomolécules Max Mousseron
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $3,290
OpenAlex ID: W7237364687
FWCI:
Cites:
Cited by:
Related to:
